Biogen Inc. Stock

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
217.8 USD -0.11% Intraday chart for Biogen Inc. -5.53% -15.83%
Sales 2024 * 9.52B Sales 2025 * 9.55B Capitalization 31.71B
Net income 2024 * 1.9B Net income 2025 * 2.21B EV / Sales 2024 * 3.65 x
Net Debt 2024 * 3.01B Net Debt 2025 * 536M EV / Sales 2025 * 3.38 x
P/E ratio 2024 *
16.8 x
P/E ratio 2025 *
14.5 x
Employees 7,570
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.11%
1 week-5.53%
Current month+1.39%
1 month+4.27%
3 months-2.64%
6 months-6.10%
Current year-15.83%
More quotes
1 week
217.06
Extreme 217.06
231.95
1 month
208.54
Extreme 208.5443
236.90
Current year
189.44
Extreme 189.44
268.30
1 year
189.44
Extreme 189.44
319.76
3 years
187.16
Extreme 187.16
468.55
5 years
187.16
Extreme 187.16
468.55
10 years
187.16
Extreme 187.16
480.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 22-11-13
Director of Finance/CFO 60 20-08-14
Chief Operating Officer - 14-12-31
Members of the board TitleAgeSince
Director/Board Member 75 09-12-31
Director/Board Member 70 19-06-18
Chairman 64 10-01-02
More insiders
Date Price Change Volume
24-05-24 217.8 -0.11% 770,943
24-05-23 218.1 -3.17% 1,068,763
24-05-22 225.2 -1.09% 1,225,658
24-05-21 227.7 -1.68% 761,248
24-05-20 231.6 +0.44% 719,121

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT

More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
217.8 USD
Average target price
286.1 USD
Spread / Average Target
+31.33%
Consensus